Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Pure Biomedicine

Request full access

A clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies

Suzhou Shi, ChinaFounded 2021Biotech & Life Sciences

About Pure Biomedicine

Based in Suzhou, China, PrimeLink Bio is a biotechnology firm established in 2021, concentrated on creating advanced drug delivery systems for cancer treatments. The company operates within the drug discovery and biotechnology sectors, with a specific focus on oncology. Its business is centered around the development of a proprietary Antibody-Drug Conjugate (ADC) technology platform. This platform is designed to be both flexible and modular, enabling the synthesis of a wide array of ADC drug candidates. Through a systematic screening process, PrimeLink Bio aims to identify the most effective ADC composition for specific targets.

The company's stated mission is to develop next-generation drug delivery systems with its own global intellectual property rights to produce first-in-class and best-in-class therapeutics. The core of its technology is a hydrophilic linker that broadens the therapeutic window for targeted therapies. PrimeLink Bio is developing a pipeline of treatments, including PLBA-001 for lung cancer, PLBA-002 for ovarian cancer, and PLBA-003 for various solid tumors. The company leverages resources from both China and the United States to advance its technology and drug development programs.

As a privately held, venture capital-backed entity, PrimeLink Bio has secured funding from investors such as Fosun Health Capital, Fosun Pharma, Kaitai Capital, and Vertex Ventures China. A Series A2 funding round in May 2024 raised $2.34 million, indicating the company is in the pre-clinical trial stage. The company serves the oncology market, with the ultimate goal of providing effective treatments for cancer patients globally. Revenue generation will likely be tied to the successful clinical development and commercialization of its therapeutic pipeline, through partnerships, licensing deals, or direct sales.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Nov 2022 $28M $110M Vertex Ventures China · Kaitai Capital · Shanghai Fosun Pharmaceutical ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Pure Biomedicine website traffic

Latest recorded traffic for Pure Biomedicine is 530 monthly website visits, down 8.6% over the last three months.

Latest monthly visits530 3-month web change-8.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Pure Biomedicine in the Suzhou Shi ecosystem

Live from Dealroom

The Pure Biomedicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Vertex Ventures China
  • Kaitai Capital
  • Shanghai Fosun Pharmaceutical
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Suzhou Shi HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Pure Biomedicine on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pure Biomedicine’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.